## Trump Administration Imposes 100% Tariffs on Patented Drugs, Revamps Metal Duties
The Trump administration has escalated its trade policy by imposing a 100% tariff on imported patented pharmaceuticals, a move that directly targets drug companies failing to meet new U.S. production or pricing demands. Announced under national-security authority, this measure applies to branded drugs and active ingredients from firms that have not secured "most-favored-nation" pricing deals with the U.S. government or committed to domestic manufacturing. The action represents a significant new front in the administration's efforts to leverage trade tools for domestic industrial and health policy goals.

Alongside the pharmaceutical tariffs, the administration announced a major overhaul of existing duties on steel, aluminum, and copper. While maintaining core 50% tariffs on many imported products, the new rules introduce exemptions for goods containing only negligible amounts of these metals. This recalibration aims to refine the broad tariffs initially imposed, potentially easing burdens on downstream manufacturers while keeping pressure on primary metal producers. The dual announcements signal a strategic shift towards more targeted, sector-specific trade enforcement.

The pharmaceutical tariff creates immediate pressure on global drugmakers, forcing a choice between accepting U.S. government price controls, shifting production to the United States, or facing prohibitive costs on their products. This policy could accelerate reshoring of pharmaceutical manufacturing but also risks disrupting supply chains for critical medicines. For metals, the revised exemptions may alleviate some trade tensions with allies and specific industries, though the underlying 50% duties remain a potent tool. Together, these actions underscore the administration's continued willingness to use executive trade powers to pursue economic and national security objectives, setting the stage for potential retaliation and market uncertainty.
---
- **Source**: ZeroHedge
- **Sector**: The Network
- **Tags**: Trade Policy, Pharmaceuticals, Tariffs, US Politics, Manufacturing
- **Credibility**: unverified
- **Published**: 2026-04-02 20:57:14
- **ID**: 47965
- **URL**: https://whisperx.ai/en/intel/47965